BAJAJ BROKING
Dr Reddy’s has launched tegoprazan 50 mg (PCAB) in India for GERD and gastric ulcers. The molecule is already approved in 21 countries, developed via a 2022 partnership with HK inno.N, and offers rapid onset with sustained gastric pH control.
Source: Dr. Reddy’s Laboratories Press Release (NSE Exchange Fillings) | Published on Sept 17, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Dr. Reddy’s Laboratories (NSE Exchange filings), on September 16, the corporation stated the launch in India of a new drug, tegoprazan, to treat acid-related gastrointestinal conditions. The drug will be marketed with the brand name PCAB in the 50 mg dosage form.
Also read: Mahindra Lifespaces to redevelop two Chembur societies worth ₹1,700 cr
Tegoprazan marketed as PCAB 50 mg in India
Targeted at GERD (erosive & non-erosive) and gastric ulcers
Molecule offers rapid onset and sustained pH control
Approval already in 21 countries; phase-III trials done in US
Partnership with HK inno.N formed in 2022
Also read: Jindal Steel in talks to acquire Thyssenkrupp Steel Europe unit
Tegoprazan is categorized as a potassium-competitive acid blocker (PCAB); this class of drugs can be compared with proton pump inhibitors (PPIs). The primary indications are erosive and non-erosive gastroesophageal reflux disease (GERD) as well as gastric ulcers. The dose of 50 mg will be available under the brand name PCAB in India.
You will see that Dr. Reddy’s struck an exclusive collaboration in 2022 with HK inno.N Corporation, based in South Korea. That agreement encompasses tegoprazan commercialisation in India and select emerging markets. The drug has already been cleared for regulatory approval in 21 jurisdictions, including South Korea and China. Phase-III studies have already been completed in the US.
It is said to exhibit a quick onset of action. You may benefit from its ability to persist in gastric pH control; this could represent a difference compared to other current forms of treatment for acid-peptic disease.
Dr. Reddy's already offers brands in the digestive health space including Omez, Razo and Vono. Tegoprazan joins that portfolio. Dr. Reddy’s Laboratories share price is priced at ₹1,310.40 a share on the BSE as of 16 Sep 2025 15:30 PM IST. The stock closed higher on that day by around 0.74%.
Feature | Detail |
Brand Name | PCAB 50 mg |
Drug Class | Potassium-Competitive Acid Blocker (PCAB) |
Indications | GERD (erosive & non-erosive), Gastric Ulcers |
Partnership | Dr Reddy’s + HK inno.N (2022) |
Approvals | 21 countries; Phase-III trials complete in US |
Also read: Apollo Hospitals launches cancer centre for women in Delhi
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading